Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919045 | 0.86 | KMT2A (0.56) | KMT2AACHESMN1; SMN2CHRM4 | |
| SCHEMBL5659414 | 0.85 | ALDH1A1 (0.41) | KMT2AACHESLC18A3KDM4EALDH1A1 | |
| SCHEMBL23269644 | 0.83 | L3MBTL1 (0.40) | KMT2AACHESMN1; SMN2SLC18A3KDM4E | |
| SCHEMBL11919058 | 0.82 | KMT2A (0.56) | KMT2AACHESMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22996224 | 0.82 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1PKM | |
| SCHEMBL22996243 | 0.82 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1PKM | |
| SCHEMBL323447 | 0.82 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1PKM | |
| SCHEMBL22996249 | 0.82 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1PKM | |
| SCHEMBL1160925 | 0.80 | KMT2A (0.51) | KMT2AACHESMN1; SMN2KDM4E | |
| SCHEMBL23269619 | 0.80 | KMT2A (0.51) | KMT2AACHESMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162203-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC. (KR) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162203-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | ERBB4, ERBB2, EGFR | KMT2A 1507/4885ACHE 4413/4885SMN1; SMN2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.